A. Trés

6.6k total citations · 2 hit papers
53 papers, 2.4k citations indexed

About

A. Trés is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A. Trés has authored 53 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 11 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. Trés's work include Cancer Treatment and Pharmacology (13 papers), Breast Cancer Treatment Studies (8 papers) and Immunotherapy and Immune Responses (7 papers). A. Trés is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), Breast Cancer Treatment Studies (8 papers) and Immunotherapy and Immune Responses (7 papers). A. Trés collaborates with scholars based in Spain, United Kingdom and United States. A. Trés's co-authors include J. Lambea, Berta Sáez, Manuel Arruebo, Nuria Vilaboa, África González‐Fernández, Gerardo F. Goya, Laura Asín, M. R. Ibarra, P. Escudero and José Mayordomo and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and JNCI Journal of the National Cancer Institute.

In The Last Decade

A. Trés

51 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Assessment of the Evolution of Cancer Treatment Therapies

2011 638 citations Berta Sáez, J. Lambea et al. profile →
Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: a review

2014 410 citations A. Trés, P. Escudero et al. profile →

Peers

Countries citing papers authored by A. Trés

Since Specialization

Citations

This map shows the geographic impact of A. Trés's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Trés with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Trés more than expected).

Fields of papers citing papers by A. Trés

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Trés. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Trés. The network helps show where A. Trés may publish in the future.

Co-authorship network of co-authors of A. Trés

This figure shows the co-authorship network connecting the top 25 collaborators of A. Trés. A scholar is included among the top collaborators of A. Trés based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Trés. A. Trés is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Gene expression‐based classifications of fibroadenomas and phyllodes tumours of the breast 2015 ·Molecular Oncology ·María Vidal, Vicente Peg, Patricia Galván, A. Trés, Javier Cortés, Santiago Ramón y Cajal, Isabel T. Rubio, Aleix Prat	28
2	Induced cell toxicity originates dendritic cell death following magnetic hyperthermia treatment 2013 ·Cell Death and Disease ·Laura Asín, Gerardo F. Goya, A. Trés, M. R. Ibarra	36
3	Controlled Cell Death by Magnetic Hyperthermia: Effects of Exposure Time, Field Amplitude, and Nanoparticle Concentration 2012 ·Pharmaceutical Research ·Laura Asín, M. R. Ibarra, A. Trés, Gerardo F. Goya	108
4	Cell death induced by the application of alternating magnetic fields to nanoparticle-loaded dendritic cells 2011 ·Nanotechnology ·Iván Marcos-Campos, Laura Asín, Teobaldo E. Torres, C. Marquina, A. Trés, M. R. Ibarra, Gerardo F. Goya	64
5	Ejercicio físico en mujeres con cáncer de mama 2010 ·Revista médica de Chile ·(unknown), (unknown), (unknown), (unknown), Victor D. Martínez, A. Trés	18
6	Dendritic cell uptake of iron‐based magnetic nanoparticles 2008 ·Cell Biology International ·Gerardo F. Goya, Iván Marcos-Campos, Rodrigo Fernández‐Pacheco, Berta Sáez, (unknown), Laura Asín, J. Lambea, (unknown), José Mayordomo, Luis Larrad, M. R. Ibarra, A. Trés	42
7	Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma 2007 ·Melanoma Research ·Carmen Visús, Raquel Andrés, José Mayordomo, María José Martínez‐Lorenzo, Laura Murillo, Berta Sáez, (unknown), (unknown), (unknown), (unknown), (unknown), Luis Larrad, A. Trés	39
8	High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial 2005 ·Annals of Oncology ·R. Charles Coombes, Anthony Howell, Marie A. Emson, Clare Peckitt, C. Gallagher, Carmelo Bengala, A. Trés, R. Joel Welch, P.A. Lawton, R.D. Rubens, E. Woods, Joanne Haviland, David M. Vigushin, Edward Kanfer, Judith M. Bliss	35
9	Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG 2005 ·Annals of Oncology ·Donato Nitti, J. Wils, (unknown), George Fountzilas, Pierfranco Conté, Cristian Sava, A. Trés, R. Charles Coombes, Diana Crivellari, Alberto Marchet, (unknown), Judith M. Bliss, Janis Homewood, M.L. Couvreur, Emma Hall, B. Barón, E. Woods, Marie A. Emson, Eric Van Cutsem, M. Lise	67
10	Biweekly Docetaxel and Vinorelbine as First-Line Chemotherapy in Metastatic Breast Cancer 2004 ·Clinical Breast Cancer ·José Mayordomo, A. Millà, Serafín Morales, Alfonso Yubero, (unknown), (unknown), (unknown), Javier Sanz, (unknown), María Jesús García García, (unknown), (unknown), A. Trés	18
11	Epirubicin–cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study 2003 ·Annals of Oncology ·(unknown), Miguel Martín, Carlos Jara, Agustí Barnadas, A. Pelegrí, A. Balil, Carlos Camps, Alessandra Frau, Álvaro Rodríguez-Lescure, José Manuel López-Vega, Juan de la Haba-Rodríguez, A. Trés, (unknown), Emilio Alba, Àngels Arcusa, A. Oltra, (unknown), (unknown), R. Pérez-Carrión, Jordi Curto	62
12	Granulocyte Colony-Stimulating Factor in the Treatment of High-Risk Febrile Neutropenia: a Multicenter Randomized Trial 2001 ·JNCI Journal of the National Cancer Institute ·Rocio García‐Carbonero, José Mayordomo, (unknown), M. López-Brea, (unknown), (unknown), Alberto Arcediano, Alfonso Yubero, (unknown), (unknown), A. Trés, José Luis Perez‐Gracia, Carlos Lumbreras, Javier Hornedo, H. Cortés-Funes, (unknown)	121
13	Combination chemotherapy with docetaxel plus vinorelbine in metastatic breast cancer patients with prior exposure to anthracyclines 2001 ·Annals of Oncology ·Juan Luis Gomez Marti, (unknown), José Mayordomo, Dolores Isla, A. Sáenz, P. Escudero, Laura Murillo, (unknown), R. Andrés, A. Trés	15
14	Cost-analysis of high-dose chemotherapy and peripheral blood stem-cell support in patients with solid tumors 2000 ·Annals of Oncology ·(unknown), José Mayordomo, (unknown), (unknown), A. Trés	9
15	Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma 1999 ·Cancer ·Albert Font, (unknown), (unknown), A. Trés, Carlos García Girón, I. Barneto, Antonio Antón, (unknown), (unknown), Rafael Rosell	24
16	Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study 1998 ·Annals of Oncology ·Enrique Aranda, Eduardo Díaz‐Rubio, Andrés Cervantes, (unknown), Alfredo Carrato, (unknown), Josep Tabernero, Javier Sastre, A. Trés, Jorge Aparicio, José Manuel López-Vega, I. Barneto, J Garcı́a-Conde	78
17	Subcutaneous ports in the radiology suite: an effective and safe procedure for care in cancer patients 1996 ·European Radiology ·M.A. De Gregorio, (unknown), Juan Ángel Fernández, Caterina Gregorio, A. Trés, E.R. Alfonso	24
18	Diet and the risk of breast cancer in Spain 1994 ·European Journal of Cancer Prevention ·(unknown), (unknown), A. Trés	100
19	Sister chromatid exchanges, proliferating rate index, and micronuclei in biomonitoring of internal exposure to vinyl chloride monomer in plastic industry workers 1991 ·Toxicology and Applied Pharmacology ·B. Sinués, A. Sanz, M.L. Bernal, A. Trés, Antonio Molina Alcalá, (unknown), (unknown), M.A. Sáenz	25
20	[Human humoral immune response to major surgery]. 1981 ·PubMed ·(unknown), (unknown), (unknown), R. Cornudella, (unknown), M. Carmen Domínguez Gutiérrez, A. Trés	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact